Related Experiment Videos
[Role of various virus genotypes in progression of chronic hepatitis C]
Insights
Hepatitis C virus (HCV) genotype 1b is common, but neither it nor other genotypes predict disease severity or fibrosis. Liver biopsy remains crucial for assessing chronic hepatitis C prognosis.
Area of Science:
- Hepatology and Viral Gastroenterology
- Molecular Virology and Diagnostics
- Clinical Pathology and Histopathology
Context:
- The etiological role of hepatitis C virus (HCV) genotypes in chronic hepatitis progression remains debated.
- Previous studies present conflicting evidence regarding the pathogenicity of HCV genotype 1b.
- Understanding genotype prevalence and impact is vital for managing HCV infection.
Purpose:
- To identify prevalent HCV genotypes in a specific patient cohort.
- To investigate the association between different HCV genotypes and the severity of chronic hepatitis C.
- To evaluate the utility of HCV genotyping in predicting disease progression and fibrosis.
Summary:
- This study analyzed 34 patients with chronic hepatitis C, determining HCV genotypes via nested PCR, LIPA, and sequencing.
- HCV genotype 1b was most prevalent (44.1%), followed by 3a (26.4%), 1a (11.7%), and 2a (2.8%). Mixed genotypes were observed in five patients.
- No significant correlation was found between HCV genotypes and liver disease activity, necrosis (ALT levels), or fibrosis stage.
- Age, however, showed a significant association with the degree of fibrosis (p < 0.01).
Impact:
- The findings suggest that HCV genotyping may not be a reliable predictor of disease severity or fibrosis in chronic hepatitis C.
- Liver biopsy remains the gold standard for assessing disease prognosis and guiding treatment decisions.
- This research contributes to understanding the complex interplay between HCV genotypes, host factors, and disease outcomes.
Abstract:
The relation between HCV genotypes and the progression of chronic hepatitis is still unknown. Some studies implied more pathogenic effect of genotype 1b for the severity of liver inflammation. However, other studies did not show the association between HCV genotype 1b and the severe outcome of HCV infection. The aim of this study was to determine the most frequent genotypes in this environment and their influence on hepatitis C severity. The investigation included 34 patients with histologically confirmed chronic hepatitis C, aged 20-65 (mean 35.0 years). On the basis of pathohistological findings, applying the modern classification, the disease activity was graded as: minimal (A1) moderate (A2) and severe (A3). The extent of fibrosis was marked as: absent (F0), mild (F1), moderate (F2) and severe (F3). Genotyping was performed by nested PCR with type-specific primers and LIPA test and verified by sequencing. The most prevailing genotype in our group of patients was 1b (44.1%), followed by genotype 3a (26.4%), genotype 1a (11.7%) and 2a (2.8%). Five patients had mixed genotypes (four 3a/1b, and one 1a/1b). The severity of liver cell necrosis, measured by alanintransferase (ALT) levels in serum was not related to any of HCV genotypes. There was no statistically significant difference between histological disease activity in relation to HCV genotypes. Stage of the disease was not significantly related to the HCV genotypes. There was a strong association between the degree of fibrosis and the age of patients (p < 0.01). These results could indicate that the determination of HCV genotypes was not useful in the estimation of disease severity and that liver biopsy was the most important for the prognosis of the disease.